LAMP study - liraglutide in patients with type 2 diabetes who have minor acute ischemic stroke or high-risk transient ischemic attack

The LAMP trial investigated the safety and efficacy of liraglutide in patients with T2D and minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA)(1).

• LAMP trial was designed as a multicenter, controlled, prospective, randomized, open-label, blinded end point trial and conducted at 27 hospitals in China from June 25, 2019, through December 27, 2023
  
• in this randomized clinical trial of 636 participants with type 2 diabetes, 25 patients (7.9%) who were randomly assigned to receive standard therapy plus liraglutide and 44 (13.8%) of those who received standard therapy had recurrent stroke at 90 days
  
• study authors concluded:
  • results of this randomized clinical trial suggest that, among Chinese patients with minor AIS or high-risk TIA who received diagnosis of T2D, treatment with liraglutide might be associated with a lower risk of recurrent stroke and improved 90-day outcomes
  • note though that given the early termination of the trial, small sample size, and limited number of outcome events, the possibility that these findings were due to chance cannot be excluded
    • larger, adequately powered studies are needed to confirm the observed effects and establish their reliability

Reference:

1. Zhu H, Yang B, Lu L, et al. Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial. JAMA Intern Med. Published online November 03, 2025.